Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 13/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.36 |
| ▸ | WEE1 | P30291 | 2/20 | 0.31 |
| ▸ | TEC | P42680 | 1/20 | 0.31 |
| ▸ | TXK | P42681 | 1/20 | 0.31 |
| ▸ | BMX | P51813 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30328204 | 1.00 | HCRTR2 (0.36) | HCRTR2HCRTR1WEE1TECTXK | |
| SCHEMBL25165014 | 0.89 | HCRTR2 (0.33) | HCRTR2HCRTR1CYP11B1CYP11B2 | |
| SCHEMBL30329562 | 0.89 | HCRTR2 (0.33) | HCRTR2HCRTR1CYP11B1CYP11B2 | |
| SCHEMBL30329510 | 0.88 | GRM2 (0.35) | HCRTR2HCRTR1GRIN1GRIN2BCYP11B1 | |
| SCHEMBL25163723 | 0.88 | GRM2 (0.35) | HCRTR2HCRTR1GRIN1GRIN2BCYP11B1 | |
| SCHEMBL25164318 | 0.88 | HCRTR2 (0.38) | HCRTR2HCRTR1KCNH2CYP11B1CYP11B2 | |
| SCHEMBL30328668 | 0.88 | HCRTR2 (0.38) | HCRTR2HCRTR1KCNH2CYP11B1CYP11B2 | |
| SCHEMBL25164484 | 0.87 | HCRTR2 (0.33) | HCRTR2HCRTR1TECTXKBMX | |
| SCHEMBL30328464 | 0.87 | HCRTR2 (0.33) | HCRTR2HCRTR1TECTXKBMX | |
| SCHEMBL25164406 | 0.87 | HCRTR2 (0.38) | HCRTR2HCRTR1GRIN1GRIN2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | HCRTR2 2687/4885HCRTR1 2849/4885WEE1 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.